McQueen Ball & Associates Inc. boosted its position in Amgen, Inc. (NASDAQ:AMGN) by 5.6% during the first quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 11,067 shares of the medical research company’s stock after buying an additional 583 shares during the period. McQueen Ball & Associates Inc.’s holdings in Amgen were worth $1,816,000 as of its most recent SEC filing.
Several other hedge funds have also recently bought and sold shares of AMGN. Thomas J. Herzfeld Advisors Inc. bought a new position in Amgen during the fourth quarter worth about $102,000. New York Life Trust Co. increased its position in Amgen by 54.8% in the third quarter. New York Life Trust Co. now owns 624 shares of the medical research company’s stock worth $104,000 after buying an additional 221 shares during the last quarter. Penserra Capital Management LLC increased its position in Amgen by 100.0% in the third quarter. Penserra Capital Management LLC now owns 684 shares of the medical research company’s stock worth $114,000 after buying an additional 342 shares during the last quarter. Oakworth Capital Inc. increased its position in Amgen by 1.4% in the third quarter. Oakworth Capital Inc. now owns 711 shares of the medical research company’s stock worth $119,000 after buying an additional 10 shares during the last quarter. Finally, Focused Wealth Management Inc increased its position in Amgen by 248.0% in the fourth quarter. Focused Wealth Management Inc now owns 870 shares of the medical research company’s stock worth $127,000 after buying an additional 620 shares during the last quarter. Institutional investors own 79.04% of the company’s stock.
Shares of Amgen, Inc. (NASDAQ:AMGN) opened at 161.61 on Monday. Amgen, Inc. has a 12 month low of $133.64 and a 12 month high of $184.21. The company has a market cap of $119.02 billion, a P/E ratio of 15.78 and a beta of 1.15. The company’s 50 day moving average is $170.79 and its 200 day moving average is $158.97.
Amgen (NASDAQ:AMGN) last announced its quarterly earnings results on Thursday, February 2nd. The medical research company reported $2.89 earnings per share for the quarter, topping the consensus estimate of $2.79 by $0.10. Amgen had a net margin of 33.59% and a return on equity of 29.42%. The firm earned $5.97 billion during the quarter, compared to analysts’ expectations of $5.75 billion. During the same quarter in the prior year, the company earned $2.61 EPS. The company’s revenue was up 7.7% compared to the same quarter last year. On average, equities research analysts predict that Amgen, Inc. will post $12.32 EPS for the current fiscal year.
The firm also recently declared a quarterly dividend, which will be paid on Thursday, June 8th. Stockholders of record on Wednesday, May 17th will be given a $1.15 dividend. The ex-dividend date of this dividend is Monday, May 15th. This represents a $4.60 annualized dividend and a dividend yield of 2.85%. Amgen’s payout ratio is presently 44.92%.
A number of equities analysts recently issued reports on the stock. Argus set a $195.00 price target on shares of Amgen and gave the stock a “buy” rating in a research note on Saturday, February 11th. Mizuho set a $195.00 price target on shares of Amgen and gave the stock a “buy” rating in a research note on Friday, March 10th. Vetr downgraded shares of Amgen from a “strong-buy” rating to a “buy” rating and set a $178.82 price target for the company. in a research note on Monday, April 3rd. Oppenheimer Holdings Inc. reissued an “outperform” rating and issued a $189.00 price target on shares of Amgen in a research note on Thursday, April 6th. Finally, BMO Capital Markets increased their price target on shares of Amgen from $197.00 to $202.00 and gave the stock a “positive” rating in a research note on Friday, February 3rd. One equities research analyst has rated the stock with a sell rating, ten have assigned a hold rating, eleven have issued a buy rating and one has assigned a strong buy rating to the company. Amgen presently has a consensus rating of “Buy” and a consensus price target of $186.94.
Amgen Company Profile
Amgen Inc is a biotechnology company. The Company discovers, develops, manufactures and delivers various human therapeutics. It operates in human therapeutics segment. Its marketed products portfolio includes Neulasta (pegfilgrastim); erythropoiesis-stimulating agents (ESAs), such as Aranesp (darbepoetin alfa) and EPOGEN (epoetin alfa); Sensipar/Mimpara (cinacalcet); XGEVA (denosumab); Prolia (denosumab); NEUPOGEN (filgrastim), and other marketed products, such as KYPROLIS (carfilzomib), Vectibix (panitumumab), Nplate (romiplostim), Repatha (evolocumab), BLINCYTO (blinatumomab), IMLYGIC (talimogene laherparepvec) and Corlanor (ivabradine).
Receive News & Ratings for Amgen Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amgen Inc. and related companies with MarketBeat.com's FREE daily email newsletter.